Advanced Malignant Tumor Clinical Trial
Official title:
An Exploratory Clinical Study of Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined With Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1) in Patients With Advanced Malignant Tumor
This is an exploratory clinical study of Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1) in patients with advanced malignant tumor.
This is an open, dose-escalation and dose-extension exploratory clinical study for patients with advanced malignancy who have failed standard therapy. In the dose-escalation phase, a fixed dose of CDP1 will be given once a week, while LDP will be given every two weeks with dose climbing. Then, cohort studies (cohorts 1 to 5) will be conducted during the dose-expansion phase. The purpose is to preliminarily evaluate the safety and efficacy of LDP combined with CDP1 in the treatment of patients with advanced malignant tumor, and to determine the recommended dose for clinical trial. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05015309 -
A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor
|
Phase 1 | |
| Not yet recruiting |
NCT06022250 -
The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor
|
Phase 1 | |
| Recruiting |
NCT06059508 -
Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05851092 -
Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Suspended |
NCT05089461 -
A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor
|
Phase 2 | |
| Active, not recruiting |
NCT04296994 -
A Study of QL1706 in Subjects With Advanced Malignant Tumor
|
Phase 1 | |
| Recruiting |
NCT05416359 -
Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04954456 -
A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04326829 -
QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05767060 -
BAT7104 Injection in Patients With Advanced Malignant Tumors.
|
Phase 1 | |
| Recruiting |
NCT04975204 -
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05144061 -
A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors
|
Phase 1 | |
| Completed |
NCT05042908 -
Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT04412564 -
A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor
|
Phase 2 | |
| Recruiting |
NCT05198505 -
Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT05318833 -
A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors
|
Phase 1 |